Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03842943 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Combination Immunotherapy for Stage III Melanoma
A Phase 2 study of Cutaneous Melanoma, sponsored by University of Louisville.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT03842943 is a Phase 2 study of Cutaneous Melanoma that is actively recruiting participants, run by University of Louisville. The registered enrollment target is 28 participants, below the 366-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03842943, a Phase 2 study of Cutaneous Melanoma, is actively recruiting participants, sponsored by University of Louisville.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
Determine safety and efficacy of pre-operative combination immunotherapy with Talimogene Laherparepvec (T-VEC)/Pembrolizumab given prior to complete lymph node dissection in resectable stage 3 cutaneous melanoma with clinically apparent lymph node metastases.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Talimogene Laherparepvec
Study Locations (1)
Kentucky
- University of Louisville - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-07-03 |
| Est. Completion | 2028-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03842943
The ClinicalTrials.gov registry entry for NCT03842943 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 366-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (92% lower). The listed sponsor is University of Louisville, which has 217 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cutaneous Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03842943 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT03842943 about?
NCT03842943 is a clinical study titled "Neoadjuvant Combination Immunotherapy for Stage III Melanoma". Determine safety and efficacy of pre-operative combination immunotherapy with Talimogene Laherparepvec (T-VEC)/Pembrolizumab given prior to complete lymph node dissection in resectable stage 3 cutaneous melanoma with clinically apparent lymph node metastases.
What is the current status of trial NCT03842943?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2019-07-03. Estimated completion is 2028-06-01.
What conditions does trial NCT03842943 study?
This clinical trial studies the following conditions: Cutaneous Melanoma.
What interventions are being tested in trial NCT03842943?
The interventions under investigation include: Pembrolizumab (DRUG), Talimogene Laherparepvec (DRUG).
Who is sponsoring clinical trial NCT03842943?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03842943 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
RECRUITING · Phase 2
-
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
RECRUITING · Phase 2
-
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
ACTIVE NOT RECRUITING · Phase 2
-
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
ACTIVE NOT RECRUITING · Phase 2
-
Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
COMPLETED · Phase 2
-
Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.